Compare Adaptive Biotechnologies Corp (ADPT) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while Vanguard S&P 500 Growth Index Fund ETF trades at $81.72. Which is the better fit depends on your goals.
| ADPT | VOOG | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $22.37 | $85.11 |
52-Week Low | $10.24 | $65.32 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
VOOG trades at $82.41, up 1.22% today, with a bullish technical outlook from moving averages but neutral oscillators. The ETF completed a 1:6 stock split in April 2026 to enhance accessibility. Recent news highlights its low 0.07% expense ratio and strong long-term growth focus on S&P 500 constituents, though short interest rose significantly in March 2026.
Outlook remains positive due to cost efficiency and growth stock exposure, but risks include tech sector volatility and high valuations. Investors benefit from diversification but should monitor market sentiment shifts amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
